Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:47:33.293Z.
Calculation as of: 2026-10-06T16:47:33.293Z.
Quote observation: 2026-10-06T16:23:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 28ff4bc206842fc4bf4b39bc6a519bf9e708a216f8b2554427075e3ddc5a9144
PEG RATIO
N/A
CytoMed Therapeutics Limited
Market Cap
$10.52M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| CytoMed Therapeutics Limited (GDTC) | $10.52M | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.65M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.34M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.68M | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.31M | N/A |
| Caring Brands, Inc. (CABR)vs › | $10.73M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | N/A |
| Cerenome, Inc. (CNSY)vs › | $11.08M | N/A |
| Lifeward Ltd. (LFWD)vs › | $9.92M | N/A |
| BioVie Inc. (BIVI)vs › | $11.12M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
